Non-Small Cell Lung Cancer (NSCLC) Therapeutics

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach US$54.0 Billion by 2030

The global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$32.8 Billion in the year 2024, is expected to reach US$54.0 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$31.3 Billion by the end of the analysis period. Growth in the Immunotherapy segment is estimated at 7.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$8.4 Billion While China is Forecast to Grow at 13.0% CAGR

The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$8.4 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 13.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market - Key Trends and Drivers Summarized

Why Are Non-Small Cell Lung Cancer (NSCLC) Therapeutics Crucial in Oncology?

Non-Small Cell Lung Cancer (NSCLC) represents the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases globally. NSCLC therapeutics are designed to target specific genetic mutations, improve patient survival rates, and reduce the side effects associated with traditional chemotherapy. Treatment modalities include surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy, with the latter two showing significant promise in improving outcomes for advanced-stage NSCLC. As the global burden of lung cancer continues to rise, NSCLC therapeutics have become a focal point in oncology, providing more personalized treatment options for patients.

What Are the Key Segments in the NSCLC Therapeutics Market?

Key treatment types include chemotherapy, targeted therapy, immunotherapy, and combination therapy, with targeted and immunotherapies experiencing rapid growth due to their effectiveness in specific genetic subtypes of NSCLC. In terms of drug class, the market includes EGFR inhibitors, ALK inhibitors, PD-1/PD-L1 inhibitors, and VEGF inhibitors, among others. Mutation-specific therapies, such as those targeting EGFR and ALK mutations, have been particularly successful in extending progression-free survival in patients. Major end-users include hospitals, cancer treatment centers, and research institutes, all of which are incorporating these advanced therapies into NSCLC management protocols.

How Are NSCLC Therapeutics Transforming Cancer Care?

Hospitals and oncology centers are integrating NSCLC therapeutics into personalized treatment plans, guided by genetic testing and biomarker analysis. Targeted therapies, such as EGFR inhibitors and ALK inhibitors, are often prescribed for patients with specific mutations, offering more effective treatment with fewer side effects compared to traditional chemotherapy. Immunotherapies, such as PD-1/PD-L1 inhibitors, are being used in both first-line and second-line settings, enhancing survival outcomes in advanced NSCLC cases. Research institutes and pharmaceutical companies are actively developing new drugs and conducting clinical trials to expand the range of effective treatments for NSCLC. Additionally, combination therapies that integrate targeted agents with immunotherapy are showing promising results in improving patient outcomes and managing resistance to single-drug treatments.

What Factors Are Driving the Growth in the NSCLC Therapeutics Market?

The growth in the NSCLC Therapeutics market is driven by several factors, including the increasing prevalence of lung cancer, which has intensified the demand for effective treatment options. Advances in genomics and personalized medicine have accelerated the development of targeted therapies, allowing for more precise treatment of specific NSCLC subtypes. The success of immunotherapy in improving survival rates has further propelled the adoption of innovative NSCLC drugs. Regulatory approvals and expanding research initiatives have also facilitated the entry of new therapeutics into the market. The growing awareness of genetic testing and biomarker identification has enhanced the adoption of targeted therapies, contributing to market growth. Additionally, government funding and investments in cancer research have supported the development of novel treatments, making NSCLC therapeutics a rapidly evolving field in oncology.

SCOPE OF STUDY:

The report analyzes the Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Therapy (Targeted Therapy, Immunotherapy, Chemotherapy); Histology (Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• AstraZeneca
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene Corp.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genentech Inc.
• GlaxoSmithKline plc
• Novartis
• Pfizer Inc.
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.